Katie Benner, Columnist

Feeling Nervous About a Biotech Bubble?

Those soaring biotech stocks raise questions about valuations in every industry.

March 9, 2015 at 5:31 PM UTC

Katie Benner is a Bloomberg View columnist who writes about technology, innovation, and the cult and culture of Silicon Valley. She lives in San Francisco. Benner previously wrote a tech and finance column for the Information. She has worked at Fortune, TheStreet.com and CNN Money, and was a freelance writer based in China covering culture, business and politics. She has a bachelor's degree in English from Bowdoin College.

Will some of these bubbles burst? Photographer: E+ via Getty Images
Source: E+ via Getty Images

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

A biotechnology bubble appears to be upon us.

The Nasdaq Biotechnology Index is hovering above 3,500. That’s more than double the level it hit 15 years ago, when investors piled into anything tech-related and got burned. The index fell from that high point and didn't begin soaring again until the late summer of 2011.